LWA
ASMB icon

Lenox Wealth Advisors’s Assembly Biosciences ASMB Stock Holding History

Lenox Wealth Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-42
Closed -$10K – 767
2019
Q4 		$10K Buy
+42
New +$7.74K ﹤0.01% 411

Other funds holding ASMB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lenox Wealth Advisors's ASMB Position: Q1 2020 in Review

Lenox Wealth Advisors sold out of Assembly Biosciences (ASMB) in Q1 2020, closing a stake of 42 shares — an estimated $10K sold.

Lenox Wealth Advisors first reported a position in ASMB in Q4 2019 and held it in 1 quarter. The position peaked at $10K in Q4 2019. 98 funds tracked by Wall St. Rank hold ASMB as of Q1 2020.

  • Lenox Wealth Advisors reported no remaining Assembly Biosciences position as of Q1 2020 after selling out during the quarter.
  • Lenox Wealth Advisors sold 42 Assembly Biosciences shares in Q1 2020, an estimated $10K.
  • Lenox Wealth Advisors first reported a position in Assembly Biosciences in Q4 2019 and held it in 1 quarter.
  • Lenox Wealth Advisors's Assembly Biosciences position peaked at $10K in Q4 2019.
  • 98 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2020.

Based on Lenox Wealth Advisors's 13F filing for Q1 2020, filed 3 Apr 2020.